Orbimed Advisors LLC Galapagos Nv Transaction History

Orbimed Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$52.3 - $71.59 $10.9 Million - $14.9 Million	-208,225 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$51.32 - $68.5 $26.1 Million - $34.9 Million	-509,032 Reduced 70.97%	208,225 $12.9 Million
Q4 2021 Feb 14, 2022	SELL	$47.03 - $57.12 $291,586 - $354,144	-6,200 Reduced 0.86%	717,257 $39.5 Million
Q3 2021 Nov 15, 2021	BUY	$52.17 - $70.2 $25.7 Million - $34.6 Million	492,552 Added 213.31%	723,457 $38.1 Million
Q1 2021 May 17, 2021	BUY	$76.15 - $111.94 $17.6 Million - $25.8 Million	230,905 New	230,905 $17.8 Million
Q4 2018 Feb 14, 2019	SELL	$87.81 - $110.65 $34.4 Million - $43.3 Million	-391,631 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$90.63 - $120.22 $8.64 Million - $11.5 Million	-95,359 Reduced 19.58%	391,631 $44 Million
Q4 2017 Feb 14, 2018	SELL	$84.48 - $104.02 $3.11 Million - $3.83 Million	-36,800 Reduced 7.03%	486,990 $45.7 Million
Q3 2017 Nov 14, 2017	BUY	$73.17 - $103.47 $38.3 Million - $54.2 Million	523,790	523,790 $53.3 Million

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.56B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.